Dianthus Therapeutics, Inc. /DE/ Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 of $0 for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 · last filed 2020-11-05
- Dianthus Therapeutics, Inc. /DE/ fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2020-09-30 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2020-06-30 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2020-03-31 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2019-12-31 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2019 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2018 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2017 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 12 month |
|---|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2020-08-06 | $0.00 derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2020-05-07 | $0.00 derived: sum of 3 quarters · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 derived: sum of 3 quarters · filed 2020-11-05 | $0.00 10-K · filed 2020-03-03 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2020-05-07 | $0.00 derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2020-05-07 | $0.00 derived: sum of 3 quarters · filed 2020-05-07 | $0.00 derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $0.00 derived: sum of 2 quarters · filed 2020-03-03 | $0.00 derived: sum of 3 quarters · filed 2020-03-03 | $0.00 10-K · filed 2020-03-03 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $0.00 derived: sum of 2 quarters · filed 2019-11-13 | $0.00 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||
| 2017-12-31 | $0.00 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |